Strong Industry Recognition CPC Scientific has been recognized as a 2026 Forbes China Industry Development Leading Enterprise, highlighting its esteemed reputation and leadership in the CRDMO sector, which can enhance credibility for prospective clients seeking reliable manufacturing partners.

Expanding Manufacturing Capacity The recent expansion to a 41,000-square-foot facility in Rocklin demonstrates significant capacity for large-scale production of synthetic peptides, offering opportunities to engage clients with high-volume manufacturing needs in therapeutics and diagnostics.

Regulatory Expertise With deep expertise in FDA and ICH guidelines, process validation, and regulatory support, CPC Scientific can serve as a trusted partner for companies aiming to navigate complex regulatory pathways for drug approval and commercialization.

Technological Capabilities The company leverages advanced technology and a flexible supply chain to accelerate project initiation and delivery, appealing to clients who require quick turnaround times in peptide and oligonucleotide development and manufacturing.

Market Position & Growth Positioned as a trusted CRO-CDMO in the peptide and oligonucleotide space with a focus on late-phase development and commercialization, CPC Scientific offers strategic opportunities for clients seeking reliable partnership throughout drug development pipeline phases.